Jazz Pharmaceuticals Sings a Sweet Tune in Q2

It was music to investors' ears the last time Jazz Pharmaceuticals (NASDAQ: JAZZ) announced its quarterly results in May. Revenue was up 14% year over year with adjusted earnings jumping 17% higher.

Jazz announced its second-quarter results after the market closed on Tuesday. Here are the highlights from the drugmaker's quarterly update.

Image source: Getty Images.

Continue reading

Quelle Fool.com